Verily, an Alphabet company formerly known as Google Life Sciences, has been working on the project — which has not been publicly announced — for several years. The team is reportedly designing a device that collects blood “painlessly” using a system of microneedles and magnets, according to CNBC.
The needles reportedly draw blood by “exploding” into a person’s skin, and are subsequently retracted by magnets, CNBC reports. Verily has explored several possible forms for the device during the past few years, including testing the idea through the use of a watch.
The project would likely not move into production for many years, in part because it would face significant technical and regulatory hurdles. However, Verily is reportedly entertaining several potential ideas for use involving the watch. The most likely use case discussed internally would be to track key blood markers for participants in clinical trials, according to the report.
Verily declined CNBC‘s request for comment.
More articles on health IT:
Phishing campaigns use these 3 applications as disguises
Elliott Management says athenahealth hasn’t responded to $7B bid
DHS issues cybersecurity warning on GE Healthcare’s ECG product: 5 notes
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.